Yesterday was International Epilepsy Day which aims to put the spotlight on a devastating disease caused by overactive nerve cells in the brain. According to WHO, epilepsy affects about 50 million people worldwide, making it one of the most common neurological diseases globally. Approximately 30 percent of patients are not helped by existing drugs. BioStock reached out to Jan Nilsson, CEO of the gene therapy company CombiGene, who next year is planning to begin studies in humans with the genetherapy candidate CG01.

The interview with Jan Nilsson »

Attachments

  • Original document
  • Permalink

Disclaimer

Combigene AB published this content on 09 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 February 2021 09:46:09 UTC.